4/12
08:02 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Medium
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
4/8
08:30 am
lucd
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
3/27
12:40 pm
lucd
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Lucid Diagnostics Inc. (NASDAQ:LUCD) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
10:08 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.80 to $3.00. They now have an "overweight" rating on the stock.
Low
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its price target lowered by analysts at Cantor Fitzgerald from $3.80 to $3.00. They now have an "overweight" rating on the stock.
3/27
08:09 am
lucd
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
Low
Report
Lucid Diagnostics Inc. (NASDAQ: LUCD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $2.50 price target on the stock.
3/25
05:42 pm
lucd
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/25
05:30 pm
lucd
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Medium
Report
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
3/21
09:38 am
lucd
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population [Yahoo! Finance]
3/21
09:30 am
lucd
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Medium
Report
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
3/20
08:30 am
lucd
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Low
Report
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
3/12
08:30 am
lucd
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
Low
Report
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
3/3
10:30 am
lucd
Health's weekend read includes kidney donations, cancer prevention, measles vaccinations and more [FOX News]
Medium
Report
Health's weekend read includes kidney donations, cancer prevention, measles vaccinations and more [FOX News]
2/27
06:10 am
lucd
Cancer prevention in the esophagus could be just a pill away, doctor says: ‘Tremendous benefit' [FOX News]
Medium
Report
Cancer prevention in the esophagus could be just a pill away, doctor says: ‘Tremendous benefit' [FOX News]
2/16
05:00 pm
lucd
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
Medium
Report
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
2/15
08:05 am
lucd
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony [Yahoo! Finance]
2/15
07:45 am
lucd
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Medium
Report
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
2/8
07:49 am
lucd
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors [Yahoo! Finance]
2/8
07:45 am
lucd
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
Medium
Report
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors